NHS England

NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS

TheĀ National Institute for Health and Care Excellence (NICE) is recommending againstĀ Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…

Life Is Better with a Local MS Nurse

I was struck down by sclerosis in 2006 ā€” literally. I was playing tennis and ran to return a drop shot. I never made it, but I did drop myself and rupture my right shoulder. It was so severe that it took two operations to rectify. The first few years…